The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
14 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $14,478,657 in first-year total cost, median $998,610.
Most frequent study sections
- Special Emphasis Panel[ZHL1 CSR-Q (F2)]5
- Special Emphasis Panel[ZHL1 CSR-S (F2)]5
- Special Emphasis Panel[ZHL1 CSR-A (F1)]4
Most frequent institutions
- BAEBIES, INC.2
- AGILE DEVICES, INC.1
- ARONORA, INC.1
- BIVACOR, INC.1
- CARDIALEN, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Rapid Navigation of Tortuous Vasculature with a Novel Steerable Coaxial Microcatheter2R44HL137521-03 | TULLY, STEPHEN | AGILE DEVICES, INC., MA | $1,007,400 | ZHL1 |
| 2021 | BiVACOR - A Physiological, Durable and Blood-Friendly Total Artificial Heart2R44HL137454-03 | TIMMS, DANIEL | BIVACOR, INC., TX | $999,517 | ZHL1 |
| 2021 | Implantable Unpinning Termination Therapy for Cardiac Arrhythmias2R44HL107055-04 | BOURN, DAVID W | CARDIALEN, INC., MO | $999,374 | ZHL1 |
| 2021 | Antithrombotic Protein C Activator for Hemodialysis2R44HL147695-03 | TUCKER, ERIK IANVERBOUT, NORAH | ARONORA, INC., OR | $998,345 | ZHL1 |
| 2021 | Improving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low Volume Blood Samples Obtained by Heel-Stick Collection2R44HL140662-06 | PAMULA, VAMSEE K. | BAEBIES, INC., NC | $912,027 | ZHL1 |
| 2020 | PLT+ Characterization and IND-Enabling Studies2R44HL131050-03 | FALB, DEAN ALAN | STELLULAR BIO, INC., MA | $2,022,100 | ZHL1 |
| 2020 | Noninvasive compact device to monitor myoglobin saturation in anemia and critical illness2R44HL127543-04A1 | ARAKAKI, LORILEE S. L. | OPTICYTE, INC., WA | $998,586 | ZHL1 |
| 2020 | Digital Microfluidics - Minimizing Blood Volume for Pediatric Coagulation Screening2R44HL125484-04 | PAMULA, VAMSEE K. | BAEBIES, INC., NC | $995,191 | ZHL1 |
| 2020 | A Phase 2a Clinical Study of a Cardiac Hormone for the Outpatient Treatment of Worsening Heart Failure2R44HL131086-02A1 | MAHAN, LAWRENCEPENN, MARC S | MADELEINE PHARMACEUTICALS, INC., WI | $887,140 | ZHL1 |
| 2019 | Automated 3D Ultrasound-based Surveillance of Arteriovenous Fistula Maturation for Post-operative Hemodialysis Patients2R44HL147423-04 | KANG, XINKUNDI, RISHI | SONAVEX, INC., MD | $999,999 | ZHL1 |
| 2019 | Iridium-electrode inhaled Nitric Oxide generator for treatment of hypoxic respiratory failure in neonates2R44HL134429-03A1 | SILKOFF, PHILIP E | THIRD POLE, INC., MA | $999,466 | ZHL1 |
| 2019 | Product and Regulatory Development of a Needle-Free Hemodialysis Access Port2R44HL126256-04A1 | MARSHALL, ANDREWTRAN, NAM T | HEALIONICS CORPORATION, WA | $998,633 | ZHL1 |
| 2019 | Plaque Risk Stratification Using Routinely Available CCTA to Optimize Therapeutic Decision-making in Patients with Known or Suspected Coronary Artery Disease2R44HL126224-03A1 | BUCKLER, ANDREW JOHN | ELUCID, MA | $991,516 | ZHL1 |
| 2019 | Towards virtual laboratory for optimizing cardiac rhythm2R44HL124901-04A1 | TICE, BROCK MICHAEL | CARDIOSOLV ABLATION TECHNOLOGIES, INC., MD | $669,363 | ZHL1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-11-0.1.2. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.